Journal of International Obstetrics and Gynecology ›› 2025, Vol. 52 ›› Issue (3): 342-349.doi: 10.12280/gjfckx.20240966
• Research on Gynecological Malignancies: Original Article • Previous Articles Next Articles
CHU Ying, WANG Yi-xuan, HUA Zhen-dan, ZHENG Jia-hui, WANG Zan-hong()
Received:
2024-10-26
Published:
2025-06-15
Online:
2025-06-19
Contact:
WANG Zan-hong
E-mail:wangzanhong@126.com
CHU Ying, WANG Yi-xuan, HUA Zhen-dan, ZHENG Jia-hui, WANG Zan-hong. Construction of A Nomogram Prognosis Prediction Model for the Prognosis of Ovarian Yolk Sac Tumors Based on SEER Database[J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 342-349.
Add to citation manager EndNote|Ris|BibTeX
变量 | 训练集 (n=266) | 验证集 (n=92) | χ2 | P |
---|---|---|---|---|
年龄(岁) | 0.206 | 0.650 | ||
<40 | 236(88.7) | 80(87.0) | ||
≥40 | 30(11.3) | 12(13.0) | ||
种族 | 3.474 | 0.176 | ||
白种人 | 159(59.8) | 57(62.0) | ||
黑种人 | 42(15.8) | 20(21.7) | ||
其他(美洲原住民、亚裔/太平洋岛民) | 65(24.4) | 15(16.3) | ||
婚姻状况 | 0.899 | 0.343 | ||
已婚 | 46(17.3) | 20(21.7) | ||
单身/离异/丧偶 | 220(82.7) | 72(78.3) | ||
肿瘤侧别 | 0.388 | 0.533 | ||
双侧 | 15(5.6) | 3(3.3) | ||
单侧 | 251(94.4%) | 89(96.7) | ||
SEER分期 | 0.314 | 0.855 | ||
局部 | 87(34.7) | 33(35.9) | ||
区域 | 80(30.1) | 26(28.3) | ||
远处转移 | 99(37.2) | 33(35.8) | ||
肿瘤最大径(mm) | 2.892 | 0.236 | ||
≤135 | 88(33.1) | 32(34.8) | ||
136~175 | 67(25.2) | 30(32.6) | ||
>175 | 111(41.7) | 30(32.6) | ||
手术 | 4.201 | 0.241 | ||
否/未知 | 6(2.3) | 6(6.5) | ||
FSS | 97(36.5) | 29(31.5) | ||
NFSS | 96(36.1) | 34(37.0) | ||
手术方式未知 | 67(25.2) | 23(25.0) | ||
化疗 | 0.001 | 0.971 | ||
否/未知 | 38(14.3) | 13(14.1) | ||
是 | 228(85.7) | 79(85.9) | ||
区域淋巴结清扫 | 0.980 | 0.322 | ||
否/未知 | 120(47.3) | 47(51.9) | ||
是 | 146(52.7) | 45(48.1) | ||
区域淋巴结阳性 | 0.978 | 0.323 | ||
否/未知 | 243(92.8) | 87(93.4) | ||
是 | 23(7.2) | 5(6.6) | ||
生存状态 | 0.775 | 0.679 | ||
存活 | 231(86.8) | 83(90.2) | ||
OTSM | 30(11.3) | 8(8.7) | ||
OCSM | 5(1.9) | 1(1.1) |
变量 | 训练集 (n=266) | 验证集 (n=92) | χ2 | P |
---|---|---|---|---|
年龄(岁) | 0.206 | 0.650 | ||
<40 | 236(88.7) | 80(87.0) | ||
≥40 | 30(11.3) | 12(13.0) | ||
种族 | 3.474 | 0.176 | ||
白种人 | 159(59.8) | 57(62.0) | ||
黑种人 | 42(15.8) | 20(21.7) | ||
其他(美洲原住民、亚裔/太平洋岛民) | 65(24.4) | 15(16.3) | ||
婚姻状况 | 0.899 | 0.343 | ||
已婚 | 46(17.3) | 20(21.7) | ||
单身/离异/丧偶 | 220(82.7) | 72(78.3) | ||
肿瘤侧别 | 0.388 | 0.533 | ||
双侧 | 15(5.6) | 3(3.3) | ||
单侧 | 251(94.4%) | 89(96.7) | ||
SEER分期 | 0.314 | 0.855 | ||
局部 | 87(34.7) | 33(35.9) | ||
区域 | 80(30.1) | 26(28.3) | ||
远处转移 | 99(37.2) | 33(35.8) | ||
肿瘤最大径(mm) | 2.892 | 0.236 | ||
≤135 | 88(33.1) | 32(34.8) | ||
136~175 | 67(25.2) | 30(32.6) | ||
>175 | 111(41.7) | 30(32.6) | ||
手术 | 4.201 | 0.241 | ||
否/未知 | 6(2.3) | 6(6.5) | ||
FSS | 97(36.5) | 29(31.5) | ||
NFSS | 96(36.1) | 34(37.0) | ||
手术方式未知 | 67(25.2) | 23(25.0) | ||
化疗 | 0.001 | 0.971 | ||
否/未知 | 38(14.3) | 13(14.1) | ||
是 | 228(85.7) | 79(85.9) | ||
区域淋巴结清扫 | 0.980 | 0.322 | ||
否/未知 | 120(47.3) | 47(51.9) | ||
是 | 146(52.7) | 45(48.1) | ||
区域淋巴结阳性 | 0.978 | 0.323 | ||
否/未知 | 243(92.8) | 87(93.4) | ||
是 | 23(7.2) | 5(6.6) | ||
生存状态 | 0.775 | 0.679 | ||
存活 | 231(86.8) | 83(90.2) | ||
OTSM | 30(11.3) | 8(8.7) | ||
OCSM | 5(1.9) | 1(1.1) |
变量 | HR(95%CI) | P |
---|---|---|
年龄(岁) | ||
<40 | 对照 | |
≥40 | 4.620(2.110~10.100) | <0.001 |
种族 | ||
白种人 | 对照 | |
黑种人 | 1.380(0.496~3.860) | 0.530 |
其他(美洲原住民、亚裔/太平洋岛民) | 1.970(0.902~4.290) | 0.089 |
婚姻状况 | ||
已婚 | 对照 | |
单身/离异/丧偶 | 0.545(0.247~1.200) | 0.130 |
肿瘤侧别 | ||
单侧 | 对照 | |
双侧 | 2.110(0.636~7.030) | 0.220 |
SEER分期 | ||
局部 | 对照 | |
区域 | 0.277(0.060~1.290) | 0.100 |
远处转移 | 2.905(1.343~6.280) | 0.007 |
肿瘤最大径(mm) | ||
≤135 | 对照 | |
136~175 | 0.599(0.208~1.720) | 0.340 |
>175 | 1.029(0.466~2.270) | 0.940 |
手术 | ||
未手术 | 对照 | |
FSS | 0.026(0.007~0.104) | <0.001 |
NFSS | 0.107(0.032~0.353) | <0.001 |
手术方式未知 | 0.031(0.007~0.132) | <0.001 |
化疗 | ||
否/未知 | 对照 | |
是 | 0.368(0.170~0.795) | 0.011 |
区域淋巴结清扫 | ||
否/未知 | 对照 | |
是 | 0.177(0.074~0.424) | <0.001 |
区域淋巴结阳性 | ||
否/未知 | 对照 | |
是 | 0.748(0.183~3.060) | 0.690 |
变量 | HR(95%CI) | P |
---|---|---|
年龄(岁) | ||
<40 | 对照 | |
≥40 | 4.620(2.110~10.100) | <0.001 |
种族 | ||
白种人 | 对照 | |
黑种人 | 1.380(0.496~3.860) | 0.530 |
其他(美洲原住民、亚裔/太平洋岛民) | 1.970(0.902~4.290) | 0.089 |
婚姻状况 | ||
已婚 | 对照 | |
单身/离异/丧偶 | 0.545(0.247~1.200) | 0.130 |
肿瘤侧别 | ||
单侧 | 对照 | |
双侧 | 2.110(0.636~7.030) | 0.220 |
SEER分期 | ||
局部 | 对照 | |
区域 | 0.277(0.060~1.290) | 0.100 |
远处转移 | 2.905(1.343~6.280) | 0.007 |
肿瘤最大径(mm) | ||
≤135 | 对照 | |
136~175 | 0.599(0.208~1.720) | 0.340 |
>175 | 1.029(0.466~2.270) | 0.940 |
手术 | ||
未手术 | 对照 | |
FSS | 0.026(0.007~0.104) | <0.001 |
NFSS | 0.107(0.032~0.353) | <0.001 |
手术方式未知 | 0.031(0.007~0.132) | <0.001 |
化疗 | ||
否/未知 | 对照 | |
是 | 0.368(0.170~0.795) | 0.011 |
区域淋巴结清扫 | ||
否/未知 | 对照 | |
是 | 0.177(0.074~0.424) | <0.001 |
区域淋巴结阳性 | ||
否/未知 | 对照 | |
是 | 0.748(0.183~3.060) | 0.690 |
变量 | HR(95%CI) | P |
---|---|---|
年龄(岁) | ||
<40 | 对照 | |
≥40 | 2.733(1.036~7.201) | 0.042 |
SEER分期 | ||
局部 | 对照 | |
区域 | 0.288(0.599~1.386) | 0.121 |
远处转移 | 1.673(0.649~4.315) | 0.287 |
手术 | ||
未手术 | 对照 | |
FSS | 0.012(0.003~0.053) | <0.001 |
NFSS | 0.023(0.007~0.081) | <0.001 |
手术方式未知 | 0.013(0.003~0.058) | <0.001 |
化疗 | ||
否/未知 | 对照 | |
是 | 0.552(0.229~1.326) | 0.184 |
区域淋巴结清扫 | ||
否/未知 | 对照 | |
是 | 0.200(0.075~0.535) | 0.001 |
变量 | HR(95%CI) | P |
---|---|---|
年龄(岁) | ||
<40 | 对照 | |
≥40 | 2.733(1.036~7.201) | 0.042 |
SEER分期 | ||
局部 | 对照 | |
区域 | 0.288(0.599~1.386) | 0.121 |
远处转移 | 1.673(0.649~4.315) | 0.287 |
手术 | ||
未手术 | 对照 | |
FSS | 0.012(0.003~0.053) | <0.001 |
NFSS | 0.023(0.007~0.081) | <0.001 |
手术方式未知 | 0.013(0.003~0.058) | <0.001 |
化疗 | ||
否/未知 | 对照 | |
是 | 0.552(0.229~1.326) | 0.184 |
区域淋巴结清扫 | ||
否/未知 | 对照 | |
是 | 0.200(0.075~0.535) | 0.001 |
[1] |
Wu H, Jiang S, Zhong P, et al. Development and identification of a prognostic nomogram model for patients with mixed cell adenocarcinoma of the ovary[J]. J Ovarian Res, 2021, 14(1):137. doi: 10.1186/s13048-021-00896-9.
pmid: 34674727 |
[2] | Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. |
[3] | Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J(Engl), 2021, 134(7):783-791. doi: 10.1097/CM9.0000000000001474. |
[4] |
Hubbard AK, Poynter JN. Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012[J]. Gynecol Oncol, 2019, 154(3):608-615. doi: 10.1016/j.ygyno.2019.06.025.
pmid: 31303255 |
[5] |
Wang T, Wang B, Wang SX, et al. Clinicopathologic Characteristics and Survival of Patients with Rare Malignant Ovarian Yolk Sac Tumors: A Population-based Analysis[J]. Curr Med Sci, 2021, 41(2):342-347. doi: 10.1007/s11596-021-2353-y.
pmid: 33877552 |
[6] | Saeed Usmani A, Yasin I, Asif RB, et al. Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review[J]. Cureus, 2022, 14(4):e24497. doi: 10.7759/cureus.24497. |
[7] |
Boyraz G, Durmus Y, Cicin I, et al. Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases[J]. Arch Gynecol Obstet, 2019, 300(1):175-182. doi: 10.1007/s00404-019-05160-6.
pmid: 30982145 |
[8] |
Nasioudis D, Mastroyannis SA, Latif NA, et al. Trends in the surgical management of malignant ovarian germcell tumors[J]. Gynecol Oncol, 2020, 157(1):89-93. doi: 10.1016/j.ygyno.2020.01.033.
pmid: 32008791 |
[9] |
Iscar T, Arean C, Chiva L, et al. Ovarian yolk sac tumor[J]. Int J Gynecol Cancer, 2021, 31(5):797-798. doi: 10.1136/ijgc-2021-002538.
pmid: 33931463 |
[10] | Ju UC, Kang WD, Kim SM. Enhancing the accuracy of preoperative and intraoperative evaluation of malignant ovarian germ cell tumors with a focus on fertility preservation in young women[J]. Int J Gynaecol Obstet, 2025, 168(3):1238-1243. doi: 10.1002/ijgo.15916. |
[11] | Qin L, Wang B, Wang Z, et al. Clinicopathological features, prognosis, and fertility outcomes in Chinese Han women treated for ovarian yolk sac tumor: A retrospective case series study from two tertiary-care academic medical centers[J]. Medicine(Baltimore), 2022, 101(29):e29868. doi: 10.1097/MD.0000000000029868. |
[12] | Guo H, Chen H, Wang W, et al. Clinicopathological Features, Prognostic Factors, Survival Trends, and Treatment of Malignant Ovarian Germ Cell Tumors: A SEER Database Analysis[J]. Oncol Res Treat, 2021, 44(4):145-153. doi: 10.1159/000509189. |
[13] | Vasta FM, Dellino M, Bergamini A, et al. Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery[J]. Biomedicines, 2020, 8(12):554. doi: 10.3390/biomedicines8120554. |
[14] | 中华医学会妇科肿瘤学分会, 中国医师协会妇产科医师分会妇科肿瘤学组, 杨佳欣, 等. 卵巢恶性生殖细胞肿瘤临床诊治中国专家共识[J]. 现代妇产科进展, 2024, 33(8):561-568. doi: 10.13283/j.cnki.xdfckjz.2024.08.001. |
[15] | Zamani N, Rezaei Poor M, Ghasemian Dizajmehr S, et al. Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences[J]. BMC Womens Health, 2021, 21(1):282. doi: 10.1186/s12905-021-01437-8. |
[16] | Turkmen O, Karalok A, Basaran D, et al. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors[J]. J Adolesc Young Adult Oncol, 2017, 6(2):270-276. doi: 10.1089/jayao.2016.0086. |
[17] | 过华蕾, 陈豪, 王文慧, 等. 保留生育功能手术及淋巴结切除对卵巢恶性生殖细胞肿瘤患者预后的影响:基于SEER数据库的研究[J]. 浙江医学, 2022, 44(20):2154-2159. doi: 10.12056/j.issn.1006-2785.2022.44.20.2022-1149. |
[18] |
Qin B, Xu W, Li Y. The impact of lymphadenectomy on prognosis and survival of clinically apparent early-stage malignant ovarian germ cell tumors[J]. Jpn J Clin Oncol, 2020, 50(3):282-287. doi: 10.1093/jjco/hyz180.
pmid: 31867612 |
[19] | Mahdi H, Swensen RE, Hanna R, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary[J]. Br J Cancer, 2011, 105(4):493-497. doi: 10.1038/bjc.2011.267. |
[20] | Wang J, Chen R, Li J, et al. The individualized significance of lymphadenectomy across all age groups and histologies in malignant ovarian germ cell tumors[J]. Arch Gynecol Obstet, 2020, 302(6):1441-1450. doi: 10.1007/s00404-020-05772-3. |
[21] | 陈雪莲, 何连利. 基于SEER数据库分析卵巢卵黄囊瘤的临床病理特征及预后影响因素[J]. 现代妇产科进展, 2022, 31(10):751-757. doi: 10.13283/j.cnki.xdfckjz.2022.10.030. |
[22] |
Li S, Zhang X, Zhang T, et al. Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors[J]. Gynecol Oncol, 2023, 178:145-152. doi: 10.1016/j.ygyno.2023.10.006.
pmid: 37865050 |
[1] | LIU Lin-lin, HUANG Xiao-wu, XIA En-lan. Reproductive Prognosis after Minimally Invasive Surgery for Herlyn-Werner-Wunderlich Syndrome [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 257-261. |
[2] | XU Ruo-lan, YANG Jiang, ZHOU Jin-ting. Application of Microfluidic Technology in the Diagnosis and Treatment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 326-330. |
[3] | FENG Xiao-yu, YAN Li-jun. The Application of Ataxia Telangiectasia Mutated and Rad3-Related Protein in the Pathogenesis, Development and Treatment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 331-336. |
[4] | ZHANG Wei-feng, ZHANG Yi. Exploration of Surgical Techniques for Transumbilical Laparoendoscopic Single-Site Surgery for Resection of Benign Ovarian Tumors [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 337-341. |
[5] | JIANG Wen-jing, DING Yong-li, LYU Qun, XIE Hui-xia, LI Ruo-peng, ZHOU Min. A Case of Giant Ovarian Leiomyoma in A Young Woman [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 350-353. |
[6] | HUANG Yin-bo, WANG Ying, LI Cui-hong, CHE Li-fan. Ovarian Steroid Cell Tumor, Not Otherwise Specified: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 354-357. |
[7] | CHEN Jia-yu, SHAO Ya-wen, PENG Hao-chen, WU Zhen-zhen. A Case of Advanced Ovarian Serous Carcinoma with Inguinal Lymph Node Metastasis [J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 357-360. |
[8] | BAI Yao-jun, WANG Si-yao, LING Fei-fei, ZHANG Sen-huai, LI Hong-li, LIU Chang. Progress of Trop-2 and Targeted Trop-2 Antibody-Coupled Drugs in Gynecological Malignant Tumors [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 1-7. |
[9] | ZHANG Yun-feng, ZHANG Wan-yue, LU Yue, WANG Yang-yang, JING Jia-yu, MU Jing-yi, WANG Yue. Research Progress of ARID1A and PIK3CA Mutations in Malignant Transformation of Ovarian Endometriosis [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 19-22. |
[10] | LI Nan, PENG Er-xuan, LIU Feng-hua. Clinical Analysis of 20 Cases of Brain Metastasis from Ovarian Epithelial Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 23-27. |
[11] | JIA Yan-feng, WU Zhen-zhen, WANG Wei-hong, WANG Yue-yuan, LI Juan. A Case of Primary Ovarian Adenosquamous Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 32-36. |
[12] | SONG Li-fang, WU Zhen-zhen, MAO Bao-hong, ZHAO Xiao-li, LIU Qing. A Case of Isolated Lymph Node Metastasis from Ovarian Cancer to the Inguinal Region [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 37-41. |
[13] | DOU Miao-miao, ZHENG Jing, ZHANG Hang, YANG Bo, ZHANG Chun-jie, LIU Zhi-jie. Diagnosis and Prognosis Analysis of Accessory Cavitated Uterine Malformations: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 84-88. |
[14] | LIU Si-min, LI Hong-li, GUO Xi, HU Ya-li, YANG Yong-xiu. Late Pregnancy with Ovarian Serous Cystadenoma Pedicle Torsion: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2024, 51(6): 632-635. |
[15] | GUO Xi, LIU Si-min, WEI Jia, YANG Yong-xiu. Malignant Transformation of Ovarian and Tube Endometriosis into Clear Cell Carcinoma: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2024, 51(6): 680-683. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||